Our work using both mouse and human sarcoma models extends these findings by showing that Atrx deletion impairs the CGAS/STING pathway and increases sarcoma susceptibility to oncolytic herpesvirus in vitro and in vivo. The gene discussed is ATRX; the disease is sarcoma.